A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Respiratory syncytial virus vaccine (Primary) ; Influenza virus vaccine
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 20 Aug 2019 Planned End Date changed from 12 Nov 2020 to 25 Dec 2020.
- 31 Jul 2019 Planned End Date changed from 30 Oct 2019 to 12 Nov 2020.
- 31 Jul 2019 Planned primary completion date changed from 30 Oct 2019 to 1 Nov 2019.